Shanghai Kehua Bio-Engineering Co.,Ltd

Shanghai Kehua Bio-Engineering Co.,Ltd

Aktie · CNE000001KC9 (XSHE)
Übersicht
AI-gestützte Analyse
Fundamental-Analyse
Was die Zahlen wirklich bedeuten – bevor der Markt es weiß.
Jetzt analysieren
News Sentiment
Kaufchance oder Alarmsignal? Was die aktuellen Nachrichten wirklich bedeuten.
Jetzt analysieren
Kaufen / Halten / Verkaufen
Kaufen, Halten oder Verkaufen? Das AI-Urteil auf einen Blick.
Jetzt analysieren
Risiko-Bewertung
Risiken erkennen, bevor sie zum Problem werden.
Jetzt analysieren
Fair Value
Zu teuer, fair bewertet oder ein Schnäppchen?
Jetzt analysieren
Neuste KI Analysen zu Shanghai Kehua Bio-Engineering Co.,Ltd
Kein Kurs
Schlusskurs XSHE 29.04.2026: 5,93 CNY
29.04.2026 07:04
Aktuelle Kurse von Shanghai Kehua Bio-Engineering Co.,Ltd
BörseTickerWährungLetzter UmsatzKursTagesveränderung
XSHE: SHENZHEN STOCK EXCHANGE
SHENZHEN STOCK EXCHANGE
002022.SZ
CNY
29.04.2026 07:04
5,93 CNY
0,05 CNY
+0,85 %
Free Float & Liquidität
Free Float 76,11 %
Shares Float 391,47 M
Ausstehende Aktien 514,35 M
Firmenprofil zu Shanghai Kehua Bio-Engineering Co.,Ltd Aktie
Shanghai Kehua Bio-Engineering Co.,Ltd researches and develops, produces, and sells in vitro diagnostic products in China. The company offers HBV, hepatitis B, HCV antibody, alpha fetoprotein quantitative, and fecal occult blood test kits; carcino-embryonic antigen quantitative determination kits; test kits for antibody to treponema pallidum and human immunodeficiency virus, and the five serological markers of hepatitis B; and diagnostic kit for syphilis rapid plasma regain. It also provides automatic biochemical analysis systems for clinical laboratories and medical institutions; nucleic acid blood screening systems; automatic chemiluminescence measuring systems; microplate readers and plate washers; general and dedicated reagent packaging systems; and electrolyte analyzers. In addition, the company researches and develops diagnostic products in the field of renal disease that provides screening diagnosis and therapeutic effect monitoring solutions for patients with various types of kidney disease. Further, it offers single-part and multi-part nucleic acid detection, and enzyme immunoassay analysis systems; reagents for blood collection agencies and clinical diagnosis; and laboratory diagnostic instruments. Additionally, the company distributes automatic chemiluminescence, microbial, and blood and urine analysis systems, as well as their supporting supplies; and automatic biochemical analyzers and other products. It also establishes third-party medical laboratory centers; provides planning and designing, management consulting, equipment and reagent supplying, and supply chain optimization services for medical laboratories, as well as medical testing services. In addition, the company is involved in the social medical undertakings. It also exports its Kehua-branded products to 38 countries and regions. The company was founded in 1981 and is based in Shanghai, the People's Republic of China.

Unternehmensdaten

Name Shanghai Kehua Bio-Engineering Co.,Ltd
Firma Shanghai Kehua Bio-Engineering Co.,Ltd
Website https://www.skhb.com
Heimatbörse XSHE SHENZHEN STOCK EXCHANGE
ISIN CNE000001KC9
Wertpapierart Aktie
Sektor Healthcare
Branche Medical - Devices
CEO Ming Li
Marktkapitalisierung 3 Mrd.
Land China
Währung CNY
Mitarbeiter 2,2 T
Adresse Caohejing Hi-Tech Park, 200233 Shanghai
IPO Datum 2004-07-21
Dividenden von 'Shanghai Kehua Bio-Engineering Co.,Ltd'
Ex-Datum Dividende pro Aktie
10.05.2023 0,60 CNY
19.07.2022 0,07 CNY
16.07.2021 0,20 CNY
09.07.2020 0,07 CNY
20.06.2019 0,07 CNY
25.05.2018 0,07 CNY
29.06.2017 0,14 CNY
29.06.2016 0,12 CNY
07.07.2015 0,20 CNY
23.04.2014 0,23 CNY

Aktien-Splits

Datum Split
27.05.2010 6:5
27.04.2009 13:10
28.04.2008 3:2
16.04.2007 3:2
20.04.2006 17:10
27.10.2005 34:25
06.04.2005 6:5

Ticker Symbole

Name Symbol
SHENZHEN STOCK EXCHANGE 002022.SZ
Weitere Aktien
Investoren, die Shanghai Kehua Bio-Engineering Co.,Ltd halten, haben auch folgende Aktien im Depot:
AB International Growth ETF
AB International Growth ETF ETF
INTERNATIONAL FINANCE CORPORATION 5.85% SYNTHETIC INR NTS 25/11/22
INTERNATIONAL FINANCE CORPORATION 5.85% SYNTHETIC INR NTS 25/11/22 Anleihe